There is a mistake in the linked article with reference to denosumab and zoledronate as it differs from the original press release and study. Zoledronate is for when disease recurrence is a priority, denosumab for fracture risks.

https://eurekalert.org/pub_releases/2017-04/iof-ngf042517.php

I thought the guideline below was interesting from a mets viewpoint. As in: if they recommend this for all postmeno early stagers with ER+ , then every ER+ postmeno metser on AIs might benefit from it as well, even without bone mets. At least in theory.

Because of the decreased incidence of bone recurrence and breast cancer specific mortality associated with bisphosphonate use, adjuvant bisphosphonates are recommended for all postmenopausal women at significant risk of disease recurrence.

For me 5 years of bisphosphonates was well worth it. I had a blood test for bone turnover each time I needed an invasive dental procedure. I gained bone density with the combination of bisphosphonates and lifting weights.

Heidihill, can you tell me more about that blood test that checked bone turnover. I've never heard of this. What are they checking? We've been monitoring my bone density every two years but I'm wondering if I should be getting this blood test to see what is going on. Thanks

Great, thanks for posing. I emailed my endocrinologist and he said that he wants to hold off on ordering any tests until we meet and review my DEXA images. BTW, he said bone marker tests can be $$ and some insurance plans don't cover the cost. Was that your experience?